Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
86.11
+1.45 (1.71%)
At close: Dec 5, 2025, 4:00 PM EST
87.73
+1.63 (1.89%)
After-hours: Dec 5, 2025, 7:59 PM EST
Corcept Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Corcept Therapeutics stock ranges from a low of $121 to a high of $150. The average analyst price target of $139 forecasts a 61.43% increase in the stock price over the next year.
Price Target: $139.00 (+61.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +68.40% | Nov 25, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +68.40% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +68.40% | Oct 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $140 | Strong Buy | Maintains | $140 | +62.59% | Sep 25, 2025 |
Financial Forecast
Revenue This Year
835.64M
from 675.04M
Increased by 23.79%
Revenue Next Year
1.18B
from 835.64M
Increased by 40.97%
EPS This Year
1.02
from 1.23
Decreased by -16.91%
EPS Next Year
1.35
from 1.02
Increased by 32.34%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 873.3M | 1.5B | ||||
| Avg | 835.6M | 1.2B | ||||
| Low | 791.7M | 994.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 29.4% | 74.5% | ||||
| Avg | 23.8% | 41.0% | ||||
| Low | 17.3% | 19.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.24 | 2.98 | ||||
| Avg | 1.02 | 1.35 | ||||
| Low | 0.79 | -0.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.7% | 191.8% | ||||
| Avg | -16.9% | 32.3% | ||||
| Low | -35.5% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.